Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by rydnhion Mar 27, 2016 12:42pm
210 Views
Post# 24703014

Roche Molecular Systems??

Roche Molecular Systems??The company signed an interim working capital loan agreement with a major shareholder, who is also one of the firm's directors, it said in a statement. The one-year loan bears a 2 percent interest rate and is repayable on demand, secured against the firm's intellectual property. "The interim working capital financing announced today provides GeneNews sufficient capital to support continuing operations in the short-term," GeneNews Executive Chairman James Howard-Tripp said in a statement. The company said it will use the funds to restructure its operations, which "may include a strategic financing, sale, merger, or other business combination," though Howard-Tripp noted that "no decision has been made with regard to these alternatives, and there is no assurance that any transaction will be entered into or consummated." Any chance this director is "Heiner Dreismann" ??? This could get interesting.gltal
Bullboard Posts